Podcasts about podcast editor

Caixin Global partners with Radio Davos to produce a podcast ahead of next week's World Economic Forum Annual Meeting of the New Champions in Tianjin. The Annual Meeting of the New Champions 2025 — AMNC25 — will bring together leaders from government, business and academia, along with innovators and representatives from international organizations, media and civil society. In this special episode (transcript) produced in collaboration with Caixin Global, World Economic Forum Managing Director Mirek Dušek sets the scene for “Summer Davos” in Tianjin, China. And Jen Zhu Scott, founding partner of IN. Capital, gives an insider's view of China and its place in the world. Guests: Mirek Dušek, Managing Director, Chief Business Officer and Head of Global Programming, World Economic Forum Li Xin, Managing Editor and Managing Director, Caixin Global Jen Zhu Scott, Founding Partner, IN. Capital Hosted by: Robin Pomeroy, Podcast Editor, World Economic Forum   Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a 66% discount. Group discounts are available — contact us for a customized plan.  

This week, I'm taking you behind the scenes of one of the most emotionally chaotic, logistically packed, spiritually sobering 48 hours I've had in a long time — but what anchored me through it all? A single sentence from a U.S. Olympian on Top Chef, of all places. It stopped me in my tracks and gave me the business pep talk I didn't know I needed: pressure is a privilege. So in this episode, we're pulling that thread — what it means, how it shows up, and why it might just be the quiet mindset shift you need if you've been feeling the weight of trying to grow something real in the middle of life being… a lot. I'm also catching you up on the chaos (garage door vandals, grief, garden wins, and Jeep purchases), sharing a Hilma product that's actually working for me, and walking through the real-time shifts I'm making inside my routine and my content rhythm. Because around here? It's part journal, part business strategy, and part reminder that growth is rarely tidy — but always worth it. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here BUSINESS NUGGET: Starts at 18:50 SEARCH BAR CONFESSIONS: Starts at 22:43 RESOURCE: Check out Hilma products – $10 off for ya! EPISODES YOU MIGHT ALSO ENJOY... EPISODE 522 – THE REFUND THAT TOOK FIVE EMAILS AND A SURVEY EPISODE 513 – WHY INSTAGRAM ALONE ISN'T ENOUGH EPISODE 473 – CANDID BUSINESS CONVERSATIONS (+ CELEBRATING 9 YRS) EPISODE 423 – POWERFUL TIME MANAGEMENT TIPS EPISODE 373 – LEGAL PAGES YOU MUST HAVE ON YOUR WEBSITE EPISODE 323 – WHY YOU SHOULD PERFORM A WEBSITE AUDIT EPISODE 273 – SO YOU WANT TO LAUNCH SOMETHING? EPISODE 223 – SETTING YOURSELF APART WITH BLOGGING EPISODE 173 – THINGS YOU SHOULD KNOW ABOUT RUNNING A BLOG  EPISODE 123 – NITTY GRITTY SERIES WITH ELISABETH MCKNIGHT FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

Got hit with a surprise charge and thought, no biggie—I'll just ask for a refund. What followed? Five emails, a survey, and a whole lot of no thanks. In this episode, I'm breaking down the hoops Rise Guide made me jump through and why that kind of customer service is a brand reputation killer. If you sell anything online, you need to hear this. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here SEARCH BAR CONFESSIONS: Starts at 8:23 BUSINESS NUGGET: Starts at 13:59 EPISODES YOU MIGHT ALSO ENJOY... EPISODE 521 – PAPER TRAILS SAVE YOU. EVERY TIME. EPISODE 512 – MAKING SPACE FOR YOURSELF EPISPODE 472 – VISIBILITY & YOUR BUSINESS EPISODE 422 – HOW TO STAY PROACTIVE WHEN BUSINESS IS SLOW EPISODE 372 – HOW TO PERFECT YOUR OFFERINGS PAGE EPISODE 322 – FRIENDSHIP BREAKUPS & HOW TO BE A BETTER FRIEND EPISODE 272 – 5 REASONS YOU SHOULD BE CREATING UNIQUE CONTENT EPISODE 222 – STAYING IN YOUR LANE EPISODE 172 – NITTY GRITTY INTERVIEW WITH JENNY MELROSE EPISODE 122 – HOW TO IMPROVE YOUR BOUNCE RATE FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

In this episode, Anika Zubair discusses the transformative impact of AI on customer success professionals. She emphasizes the importance of embracing AI to alleviate administrative burdens, avoid common mistakes in its adoption, and maximize its potential in daily tasks. Anika provides practical applications of AI in discovery calls, quarterly business reviews, and renewal forecasting, highlighting how it can save time and enhance strategic decision-making. She also introduces her new guide on training AI to be a revenue-generating co-pilot for customer success professionals.Train AI to be Your Revenue Generating Co-Pilot Guide: https://www.thecustomersuccesspro.com/offers/P66P25Uw/checkout?coupon_code=PODCAST50Use the discount code: PODCAST50Chapters00:00 The Rise of AI in Customer Success02:51 Overcoming Administrative Burdens with AI06:07 Common Mistakes in AI Adoption09:03 Maximizing AI's Potential in Customer Success11:54 Practical Applications of AI in Daily Tasks15:06 Transforming Discovery Calls and QBRs with AI17:58 Forecasting Renewals and Managing Customer Relationships21:12 Introducing the AI Co-Pilot Guide24:04 Running with AI26:57 RecapConnect with Anika Zubair:Website: https://thecustomersuccesspro.com/LinkedIn:  https://www.linkedin.com/in/anikazubair/CSM RevUP Academy: https://thecustomersuccesspro.com/revupSend Anika a text :) Want to be our next guest? Apply here: https://www.thecustomersuccesspro.com/podcast-guest Podcast Editor: https://podcastmagician.com/

Quick and gritty update before I hit the road — I'm headed to Colorado, my garden's exploding, and oh yeah, business is throwing curveballs left and right. From audits and attorneys to hitting 1K on TikTok, I'm walking you through the real stuff: what's working, what's frustrating, and why your paper trail might just be your best business asset. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here BUSINESS NUGGET: Starts at 12:19 EPISODES YOU MIGHT ALSO ENJOY... EPISODE 520 – YOU'RE NOT BEHIND – YOU'RE BUILDING WHAT WORKS (FOR NOW) EPISODE 511 – FEARLESS VISIBILITY IN YOUR BUSINESS EPISODE 471 – HOW TO BE MORE VISIBLE EPISODE 421 – BUSINESS LESSONS LEARNED IN 8 YEARS OF PODCASTING EPISODE 371 – HOW TO PERFECT YOUR ABOUT PAGE EPISODE 321 – WHY YOU NEED A PRODUCT TO SELL EPISODE 271 – LEGAL STUFF & YOUR BIZ WITH CAROLINE FOX EPISODE 221 – SHOULD YOU START A PODCAST? EPISODE 171 – HOW TO KICK THE OVERWHELM EPISODE 121 – NITTY GRITTY SERIES WITH ALEXANDRA EVJEN FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

In this episode of the Customer Success Pro Podcast, host Anika Zubair and guest Parul Bhandari discuss the critical aspects of building effective customer retention programs. They explore the importance of understanding customer goals, the role of product market fit, and the necessity of tracking essential metrics from day one. Parul shares her journey from leading customer success teams to becoming a fractional consultant, emphasizing the growing trend of fractional roles in the current market. The conversation highlights the need for early-stage startups to prioritize retention strategies alongside acquisition efforts, ensuring a solid foundation for long-term success. In this conversation, Anika Zubair discusses the evolution of customer retention strategies as organizations grow. She emphasizes the importance of understanding customer health, structuring effective renewal processes, and adapting to changes in customer sentiment and stakeholder dynamics. Anika also highlights the need for continuous engagement with customers and the role of health scores in retention efforts. The discussion covers practical steps for building retention programs and the significance of viewing challenges as opportunities for growth.Get your FREE QBR Revenue Guide: https://thecustomersuccesspro.com/resourcesSignup to the VIP Waitlist for RevUP Academy: https://thecustomersuccesspro.com/revupChapters00:00 Introduction08:13 The Importance of Early Stage Customer Success12:09 Creating Retention Programs from Day One13:37 Understanding Customer Goals and Outcomes16:21 The Role of Product Market Fit in Retention20:12 Tracking Metrics for Early Stage Companies25:31 Essential Metrics for Customer Retention27:53 Identifying Customer Retention Challenges28:23 Evolving Retention Strategies for Growing Teams29:46 Understanding Customer Health and Renewal Programs31:14 Structuring Effective Renewal Processes32:42 Navigating Customer Sentiment and Product Changes34:57 Re-Onboarding and Stakeholder Realignment36:54 Leveraging Health Scores for Retention39:42 Transforming Challenges into Opportunities41:07 Surprises in Mature Retention Phases43:05 Engaging Customers for Long-Term Retention45:27 Keeping Retention Strategies Fresh49:12 Practical Steps for Building Retention ProgramsConnect with Anika Zubair: Website: https://thecustomersuccesspro.com/LinkedIn:  https://www.linkedin.com/in/anikazubair/CSM RevUP Academy: https://thecustomersuccesspro.com/revupConnect with Parul Bhandari:Linkedin: https://www.linkedin.com/in/parul-bhandari-1294488/Website: https://customerxsuccess.com/Parul is a Customer Success consultant based in Chicago. Following time working for large corporations, Parul launched her first Customer Success (CS) team from the ground up, and from then on has found a passion in leading CS teams. Parul draws from her collective background to design CS organizations which can be scaled successfully, to drive CS as a profit center and to drive value exchange and retention.Parul writes for Inc.com and has a collaborative CS booSend Anika a text :) Want to be our next guest? Apply here: https://www.thecustomersuccesspro.com/podcast-guest Podcast Editor: https://podcastmagician.com/

Feeling stuck in a season that's just… a lot? This week, I'm sharing the behind-the-scenes of a wild work stretch, falling (literally), and the real question I'm asking to stay grounded: What's right for me right now? If you've been second-guessing your next move, this one's for you. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here BUSINESS NUGGET: Starts at 12:19 EPISODES YOU MIGHT ALSO ENJOY... EPISODE 519 – GIVING YOURSELF GRACE WHEN EVERYTHING'S A LOT EPISODE 510 – BUSINESS STRATEGIES FOR GROWTH EPISODE 470 – FINDING YOUR BUSINESS SUPER POWER EPISODE 420 – HOW TO CREATE A MARKETING ACTIVITY PLAN EPISODE 370 – HOW TO PERFECT YOUR WEBSITE HOMEPAGE EPISODE 320 – CHECK YOUR MEAN GIRL AT THE DOOR EPISODE 270 – BUSINESS TOOLS & APPS I'M USING IN 2020 EPISODE 220 – BUILDING YOUR BRAND STORY EPISODE 170 – STUCK IN A HOLDING PATTERN? EPISODE 120 – DISCLOSURES: AN INTERVIEW WITH THE FTC FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

In this episode of the Customer Success Pro Podcast, Anika Zubair emphasizes the importance of building genuine human relationships with customers. She discusses the challenges faced by Customer Success Managers in managing multiple accounts and the need to shift from transactional interactions to strategic partnerships. Anika outlines common mistakes CSMs make, such as only reaching out when they need something and failing to personalize communication. She introduces principles for building strong relationships, including being relevant, consistent, and human. The episode concludes with actionable challenges for listeners to enhance their customer relationships.Get your FREE QBR Revenue Guide: https://thecustomersuccesspro.com/resourcesGet on the VIP Waitlist for RevUP Academy: https://www.thecustomersuccesspro.com/revupChapters:00:00 Building Lasting Customer Relationships02:15 Customer Management in CS05:34 Myths in Customer Success10:10 Principles of Strategic Relationships15:44 Consistency Over Intensity19:34 The Human Element in Customer Success22:18 Actionable TakeawaysConnect with Anika Zubair: Website: https://thecustomersuccesspro.com/LinkedIn:  https://www.linkedin.com/in/anikazubair/CSM RevUP Academy: https://thecustomersuccesspro.com/revupSend Anika a text :) Want to be our next guest? Apply here: https://www.thecustomersuccesspro.com/podcast-guest Podcast Editor: https://podcastmagician.com/

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Cardiac Output Estimation in the Intensive Care Unit.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Risk of Myocardial Infarction in Patients With Aortic Stenosis: Insights From the VALVENOR Registry.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Value of Pericoronary Fat Attenuation Index on Computed Tomography for Hospitalization for Heart Failure.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Automated, Standardized, Quantitative Analysis of Cardiovascular Borders on Chest X-Rays Using Deep Learning.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism: A Target Trial Emulation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Psychological Distress and Cardiovascular Health in Pregnancy: Findings From the U.S. National Health Interview Survey.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Systolic and Diastolic Blood Pressure, Cardiac Biomarkers, and Cardiovascular Mortality in Adults Without Cardiovascular Disease.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Cardiomyopathy Prevalence and Pregnancy-Related Mortality: United States, 2010 to 2020.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Healthcare Expenditure on Atrial Fibrillation in the United States: The Medical Expenditure Panel Survey 2016 to 2021.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prevalence, Risk Factors, and Prognosis for Fontan-Associated Liver Disease: A Systematic Review and Exploratory Meta-Analysis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on MYH7 Mutations in Restrictive Cardiomyopathy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Concussions Are Associated With Increases in Blood Pressure and Cardiovascular Risk in American-Style Football Athletes.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Investigating the Anrep Effect in Hypertrophic Obstructive Cardiomyopathy With Invasive Pressure-Volume Analysis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Very Long-Term Outcomes of Cardiac Resynchronization Therapy in Patients With Ischemic and Nonischemic Cardiomyopathy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Genotype-Negative Patients With Familial Hypertrophic Cardiomyopathy: Traveling to the “Middle Earth”.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Targeting Investigation and Treatment in Type 2 Myocardial Infarction: A Pilot Randomized Controlled Trial.

If you've been feeling like you're carrying too much and still not doing enough—you're not alone. This episode is a real-time snapshot of what it looks like to juggle a packed life and still choose softness over self-criticism. I'm sharing updates on my trays journey (almost done!), content strategy progress, garden harvests, and the house build… but more importantly, I'm naming the overwhelm and offering permission to let a few things slide. Because giving yourself grace is a strategy—and sometimes, it's the most important one. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here BUSINESS NUGGET: Starts at 8:00 EPISODES YOU MIGHT ALSO ENJOY... EPISODE 519 – HOW I'M USING CHATGPT + TRELLO TO MANAGE 3 BRANDS WITHOUT LOSING MY MIND EPISODE 509 – THE ONE ABOUT JOY VS HAPPINESS EPISODE 469 – UNPOPULAR BUSINESS OPINION EPISODE 419 – HOW CREATIVITY CAN FUEL US EPISODE 369 – 8 THINGS I WISH I DID DIFFERENTLY AT THE LAUNCH OF THIS BUSINESS EPISODE 319 – MAKE SURE YOUR CONTRACTS HAVE THESE KEY THINGS IN THEM EPISODE 269 – COURAGE & CLARITY WITH VIDEO CONTENT EPISODE 219 – 6 THINGS YOU CAN TRY RIGHT NOW TO GROW YOUR FOLLOWERS EPISODE 169 – OLD SCHOOL BLOGGING STRATEGY EPISODE 119 – NITTY GRITTY SERIES WITH JANSSEN BRADSHAW FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

In this episode, Anika Zubair discusses the importance of transitioning from a reactive to a proactive customer success strategy. She outlines a step-by-step approach to building a proactive customer success organization, emphasizing the need to define success from the customer's perspective, map the customer journey, automate touchpoints, and regularly review strategies. The episode provides actionable insights for customer success professionals to enhance their effectiveness and drive customer outcomes.Get your FREE QBR Revenue Guide: https://thecustomersuccesspro.com/resourcesChapters00:00 The Shift from Reactive to Proactive Customer Success03:05 Building a Proactive Customer Success Strategy05:57 Defining Success for Customers08:47 Mapping the Customer Journey12:07 Automating Touch Points for Efficiency15:00 Creating a Risk and Opportunity Framework17:49 The Importance of Regular Strategy ReviewConnect with Anika Zubair: Website: https://thecustomersuccesspro.com/LinkedIn:  https://www.linkedin.com/in/anikazubair/CSM RevUP Academy: https://thecustomersuccesspro.com/revupSend Anika a text :) Want to be our next guest? Apply here: https://www.thecustomersuccesspro.com/podcast-guest Podcast Editor: https://podcastmagician.com/

JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.” Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multigene panels compared with single-gene BRAF testing to guide therapeutic decisions in advanced melanoma. Transcript Dr. Rafeh Naqash:Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center in the University of Oklahoma. Today, we are excited to be joined by Dr. Dean A. Regier, Director at the Academy of Translational Medicine, Associate Professor at the School of Population and Public Health, UBC Senior Scientist at the British Columbia Cancer Research Institute, and also the senior author of the JCO Precision Oncology article entitled "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." At the time of this recording, our guest's disclosures will be linked in the transcript. Dean, welcome to our podcast and thank you for joining us today. Dr. Dean Regier:Thank you. I'm delighted to be here. Dr. Rafeh Naqash:So, obviously, you are from Canada, and medicine, or approvals of drugs to some extent, and in fact approvals of gene testing to some extent is slightly different, which we'll come to learn about more today, compared to what we do in the US—and in fact, similarly, Europe versus North America to a large extent as well. Most of the time, we end up talking about gene testing in lung cancer. There is a lot of data, a lot of papers around single-gene panel testing in non-small cell lung cancer versus multigene testing. In fact, a couple of those papers have been published in JCO PO, and it has shown significant cost-effectiveness and benefit and outcomes benefit in terms of multigene testing. So this is slightly, you know, on a similar approach, but in a different tumor type. So, could you tell us first why you wanted to investigate this question? What was the background to investigating this question? And given your expertise in health economics and policy, what are some of the aspects that one tends or should tend to understand in terms of cost-effectiveness before we go into the results for this very interesting manuscript? Dr. Dean Regier:Yeah, of course, delighted to. So, one of the reasons why we're deeply interested in looking at comparative outcomes with respect to single- versus multigene testing— whether that's in a public payer system like Canada or an insurer system, a private system in the United States— is that the question around does multigene versus single-gene testing work, has not typically tested in randomized controlled trials. You don't have people randomized to multigene versus single-gene testing. And what that does, it makes the resulting evidence base, whether it's efficacy, safety, or comparative cost-effectiveness, highly uncertain. So, the consequence of that has been uneven uptake around the world of next-generation sequencing panels. And so if we believe that next-gen sequencing panels are indeed effective for our patients, we really need to generate that comparative evidence around effectiveness and cost-effectiveness. So we can go to payers, whether it be single payer or a private insurer, to say, "Here are the comparative outcomes." And when I say that uptake has been uneven, uptake there's been actually plenty, as you know, publications around that uneven uptake, whether it be in Europe, in the United States, in Canada. And so we're really interested in trying to produce that evidence to create the type of deliberations that are needed to have these types of technologies accessible to patients. And part of those deliberations, of course, is the clinical, but also in some contexts, cost-effectiveness. And so, we really start from the perspective of, can we use our healthcare system data, our learning healthcare system, to generate that evidence in a way that emulates a randomized controlled trial? We won't be able to do these randomized controlled trials for various, like really important and and reasons that make sense, quite frankly. So how can we mimic or emulate randomized controlled trials in a way that allows us to make inference around those outcomes? And for my research lab, we usually think through how do we do causal inference to address some of those biases that are inherent in observational data. So in terms of advanced melanoma, we were really interested in this question because first of all, there have been no randomized controlled trials around next-gen sequencing versus single-gene testing. And secondly, these products, these ICIs, immune checkpoint inhibitors, and BRAF and MEK inhibitors, they are quite expensive. And so the question really becomes: are they effective? And if so, to what extent are they cost-effective? Do they provide a good reason to have information around value for money? Dr. Rafeh Naqash:So now going to the biology of melanoma, so we know that BRAF is one of the tumor-agnostic therapies, it has approvals for melanoma as well as several other tumor types. And in fact, I do trials with different RAF-RAS kinase inhibitors. Now, one of the things that I do know is, and I'm sure some of the listeners know, is the DREAMseq trial, which was a melanoma study that was an NCI Cooperative Group trial that was led by Dr. Mike Atkins from Georgetown a couple of years back, that did show survival benefit of first-line immunotherapy sequencing. It was a sequencing study of whether to do first-line BRAF in BRAF-mutant melanoma followed by checkpoint inhibitors, or vice versa. And the immune checkpoint inhibitors followed by BRAF was actually the one that showed benefit, and the trial had to stop early, was stopped early because of the significant benefit seen. So in that context, before we approach the question of single-gene versus multigene testing in melanoma, one would imagine that it's already established that upfront nivolumab plus ipilimumab, for that matter, doublet checkpoint inhibitor therapy is better for BRAF-mutant melanoma. And then there's no significant other approvals for melanoma for NRAS or KIT, you know, mucosal melanomas tend to have KIT mutations, for example, or uveal melanomas, for that matter, have GNAQ, and there's no targeted therapies. So, what is the actual need of doing a broader testing versus just testing for BRAF? So just trying to understand when you started looking into this question, I'm sure you kind of thought about some of these concepts before you delved into that. Dr. Dean Regier:I think that is an excellent question, and it is a question that we asked ourselves: did we really expect any differences in outcomes between the testing strategies? And what did the real-world implementation, physician-guided, physician-led implementation look like? And so, that was kind of one of the other reasons that we really were interested is, why would we go to expanded multigene panel sequencing at all? We didn't really expect or I didn't expect an overall survival a priori. But what we saw in our healthcare system, what happened in our healthcare system was the implementation in 2016 of this multigene panel. And this panel covered advanced melanoma, and this panel cost quite a bit more than what they were doing in terms of the single-gene BRAF testing. And so when you're a healthcare system, you have to ask yourself those questions of what is the additional value associated with that? And indeed, I think in a healthcare system, we have to be really aware that we do not actually follow to the ideal extent randomized controlled trials or trial settings. And so that's the other thing that we have to keep in mind is when these, whether it's an ICI or a BRAF MEK inhibitor, when these are implemented, they do not look like randomized controlled trials. And so, we really wanted to emulate not just a randomized controlled trial, but a pragmatic randomized controlled trial to really answer those real-world questions around implementation that are so important to decision making. Dr. Rafeh Naqash:Sure. And just to understand this a little better: for us in the United States, when we talk about multigene testing, we generally refer to, these days, whole-exome sequencing with whole-transcriptome sequencing, which is like the nuclear option of of the testings, which is not necessarily cheap. So, when you talk about multigene testing in your healthcare system, what does that look like? Is it a 16-gene panel? Is it a 52-gene panel? What is the actual makeup of that platform? Dr. Dean Regier:Excellent question. Yeah, so at the time that this study is looking at, it was 2016, when we, as BC Cancer—so British Columbia is a population right now of 5.7 million people, and we have data on all those individuals. We are one healthcare system providing health care to 5.7 million people. In 2016, we had what I call our "home-brew" multigene panel, which was a 53-gene panel that was reimbursed as standard of care across advanced cancers, one of them being advanced melanoma. We have evolved since then. I believe in 2022, we are using one of the Illumina panels, the Focus panel. And so things have changed; it's an evolving landscape. But we're specifically focused on the 53-gene panel. It was called OncoPanel. And that was produced in British Columbia through the Genome Sciences Centre, and it was validated in a single-arm trial mostly around validity, etc. Dr. Rafeh Naqash:Thank you for explaining that. So now, onto the actual meat and the science of this project. So, what are some of the metrics from a health economy standpoint that you did look at? And then, methodology-wise, I understand, in the United States, we have a fragmented healthcare system. I have data only from my institution, for that matter. So we have to reach out to outside collaborators and email them to get the data. And that is different for you where you have access to all the data under one umbrella. So could you speak to that a little bit and how that's an advantage for this kind of research especially? Dr. Dean Regier:Yeah. In health economics, we look at the comparative incremental costs against the incremental effectiveness. And when we think about incremental costs, we think not just about systemic therapy or whether you see a physician, but also about hospitalizations, about all the healthcare interactions related to oncology or not that a patient might experience during their time or interactions with the healthcare system. You can imagine with oncology, there are multiple interactions over a prolonged time period depending on survival. And so what we try to do is we try to—and the benefit of the single-payer healthcare system is what we do is we link all those resource utilization patterns that each patient encounters, and we know the price of that encounter. And we compare those incremental costs of, in this case, it's the multigene panel versus the single-gene panel. So it's not just the cost of the panel, not just the cost of systemic therapy, but hospitalizations, physician encounters, etc. And then similarly, we look at, in this case, we looked at overall survival - we can also look at progression-free survival - and ask the simple question, you know, what is the incremental cost per life-year gained? And in that way, we get a metric or an understanding of value for money. And how we evaluate that within a deliberative priority setting context is we look at safety and efficacy first. So a regulatory package that you might get from, in our case, Health Canada or the FDA, so we look at that package, and we deliberate on, okay, is it safe and is it effective? How many patients are affected, etc. And then separately, what is the cost-effectiveness? And at what price, if it's not cost-effective, at what price would it be cost-effective? Okay, so for example, we have this metric called the incremental cost-effectiveness ratio, which is incremental cost in the numerator, and in this case, life-years gained in the denominator. And if it is around $50,000 or $100,000 per life-year gained—so if it's in that range, this ratio—then we might say it's cost-effective. If it's above this range, which is common in oncology, especially when we talk about ICIs, etc., then you might want to negotiate a price. And indeed, when we negotiate that price, we use the economic evaluation, that incremental cost-effectiveness ratio, as a way to understand at what price should we negotiate to in order to get value for money for the healthcare system. Dr. Rafeh Naqash:Thank you for explaining those very interesting terminologies. Now, one question I have in the context of what you just mentioned is, you know, like the drug development space, you talked about efficacy and safety, but then on the safety side, we talk about all-grade adverse events or treatment-related adverse events—two different terminologies. From a healthcare utilization perspective, how do you untangle if a patient on a BRAF therapy got admitted for a hypoxic respiratory failure due to COPD, resulting in a hospitalization from the cost, overall cost utilization, or does it not matter? Dr. Dean Regier:We try to do as much digging into those questions as possible. And so, this is real-world data, right? Real-world data is not exactly as clean as you'd get from a well-conducted clinical trial. And so what we do is we look at potential adverse event, whether it's hospitalization, and the types of therapies around that hospitalization to try- and then engage with clinicians to try to understand or tease out the different grades of the adverse event. Whether it's successful or not, I think that is a real question that we grapple with in terms of are we accurate in delineating different levels of adverse events? But we try to take the data around the event to try to understand the context in which it happens. Dr. Rafeh Naqash:Thank you for explaining that, Dean. So, again to the results of this manuscript, could you go into the methodology briefly? Believe you had 147 patients, 147 patients in one arm, 147 in the other. How did you split that cohort, and what were some of the characteristics of this cohort? Dr. Dean Regier:So, the idea, of course, is that we have selection criteria, study inclusion criteria, which included in our case 364 patients. And these were patients who had advanced melanoma within our study time period. So that was 2016 to 2018. And we had one additional year follow. So we had three total years. And what we did is that we linked our data, our healthcare system data. During this time, because the policy change was in 2016, we had patients both go on the multigene panel and on the single-gene BRAF testing. So, the idea was to emulate a pragmatic randomized controlled trial where we looked at contemporaneous patients who had multigene panel testing versus single-gene BRAF testing. And then we did a matching procedure—we call it genetic matching. And that is a type of matching that allows us to balance covariates across the patient groups, across the multigene versus BRAF testing cohorts. The idea again is, as you get in a randomized controlled trial, you have these baseline characteristics that look the same. And then the hope is that you address any source selection or confounding biases that prohibit you to have a clean answer to the question: Is it effective or cost-effective? So you address all those biases that may prohibit you to find a signal if indeed a signal is there. And so, what we did is we created—we did this genetic matching to balance covariates across the two cohorts, and we matched them one-to-one. And so what we were able to do is we were able to find, of those 364 patients in our pool, 147 in the multigene versus 147 in the single-gene BRAF testing that were very, very similar. In fact, we created what's called a directed acyclic graph or a DAG, together with clinicians to say, “Hey, what biases would you expect to have in these two cohorts that might limit our ability to find a signal of effectiveness?” And so we worked with clinicians, with health economists, with epidemiologists to really understand those different biases at play. And the genetic matching was able to match the cohorts on the covariates of interest. Dr. Rafeh Naqash:And then could you speak on some of the highlights from the results? I know you did survival analysis, cost-effectiveness, could you explain that in terms of what you found? Dr. Dean Regier:We did two analyses. The intention-to-treat analysis is meant to emulate the pragmatic randomized controlled trial. And what that does is it answers the question, for all those eligible for multigene or single-gene testing: What is the cost-effectiveness in terms of incremental life-years gained and incremental cost per life-years gained? And the second one was around a protocol analysis, which really answered the question of: For those patients who were actually treated, what was the incremental effectiveness and cost-effectiveness? Now, they're different in two very important ways. For the intention-to-treat, it's around population questions. If we gave single-gene or multigene to the entire population of advanced melanoma patients, what is the cost-effectiveness? The per-protocol is really around that clinical question of those who actually received treatment, what was the incremental cost and effectiveness? So very different questions in terms of population versus clinical cost and effectiveness. So, for the intention-to-treat, what we found is that in terms of life-years gained is around 0.22, which is around 2.5 months of additional life that is afforded to patients who went through the multigene panel testing versus the single-gene testing. That was non-statistically significant from zero at the 5% level. But on average, you would expect this additional 2.5 months of life. The incremental costs were again non-statistically significant, but they're around $20,000. And so when we look at incremental cost-effectiveness, we can also look at the uncertainty around that question, meaning what percentage of incremental cost-effectiveness estimates are likely to be cost-effective at different willingness-to-pay thresholds? Okay? So if you are willing to pay $100,000 to get one gain of life-years, around 52.8% of our estimates, in terms of when we looked at the entire uncertainty, would be cost-effective. So actually that meets the threshold of implementation in our healthcare system. So it's quite uncertain, just over 50%. But what we see is that decision-makers actually have a high tolerance for uncertainty around cost-effectiveness. And so, while it is uncertain, we would say that, well, the cost-effectiveness is finely balanced. Now, when we looked at the population, the per-protocol population, those folks who just got treatment, we actually have a different story. We have all of a sudden around 4.5 or just under 5 months of life gained that is statistically significantly different from zero, meaning that this is a strong signal of benefit in terms of life-years gained. In terms of the changes in costs or the incremental costs, they are larger again, but statistically insignificant. So the question now is, to what extent is it cost-effective? What is the probability of it being cost-effective? And at the $100,000 per life-year gained willingness-to-pay, there was a 73% chance that multigene panel testing versus single-gene testing is cost-effective. Dr. Rafeh Naqash:So one of the questions I have here, this is a clarification both for myself and maybe the listeners also. So protocol treatment is basically if you had gene testing and you have a BRAF in the multigene panel, then the patient went on a BRAF treatment. Is that correct? Dr. Dean Regier:It's still physician choice. And I think that's important to say that. So typically what we saw in both in our pre- and post-matching data is that we saw around 50% of patients, irrespective of BRAF status, get an ICI, which is appropriate, right? And so the idea here is that you get physician-guided care, but if the patient no longer performs on the ICI, then it gives them a little bit more information on what to do next. Even during that time when we thought it wasn't going to be common to do an ICI, but it was actually quite common. Dr. Rafeh Naqash:Now, did you have any patients in this study who had the multigene testing done and had an NRAS or a KIT mutation and then went on to those therapies, which were not captured obviously in the single-gene testing, which would have just tried to look at BRAF? Dr. Dean Regier:So I did look at the data this morning because I thought that might come up in terms of my own questions that I had. I couldn't find it, but what we did see is that some patients went on to clinical trials. So, meaning that this multigene panel testing allowed, as you would hope in a learning healthcare system, patients to move on to clinical trials to have a better chance at more appropriate care if a target therapy was available. Dr. Rafeh Naqash:And the other question in that context, which is not necessarily related to the gene platform, but more on the variant allele frequency, so if you had a multigene panel that captured something that was present at a high VAF, with suspicion that this could be germline, did you have any of those patients? I'm guessing if you did, probably very low number, but I'm just thinking from a cost-effective standpoint, if you identify somebody with germline, their, you know, first-degree relative gets tested, that ends up, you know, prevention, etc. rather than somebody actually developing cancer subsequently. That's a lot of financial gains to the system if you capture something early. So did you look at that or maybe you're planning to look at that? Dr. Dean Regier:We did not look at that, but that is a really important question that typically goes unanswered in economic evaluations. And so, the short answer is yes, that result, if there was a germline finding, would be returned to the patient, and then the family would be able to be eligible for screening in the appropriate context. What we have found in economic evaluations, and we've recently published this research, is that that scope of analysis is rarely incorporated into the economic evaluation. So those downstream costs and those downstream benefits are ignored. And when you- especially also when you think about things like secondary or incidental findings, right? So it could be a germline finding for cancer, but what about all those other findings that we might have if you go with an exome or if you go with a genome, which by the way, we do have in British Columbia—we do whole-genome and transcriptome sequencing through something called the Personalized OncoGenomics program. That scope of evaluation, because it's very hard to get the right types of data, because it requires a decision model over the lifetime of both the patients and potentially their family, it becomes very complicated or complex to model over patients' and families' lifetime. That doesn't mean that we should not do it, however. Dr. Rafeh Naqash:So, in summary Dean, could you summarize some of the known and unknowns of what you learned and what you're planning in subsequent steps to this project? Dr. Dean Regier:Our North Star, if you will, is to really understand the entire system effect of next-generation sequencing panels, exome sequencing, whole genomes, or whole genomes and transcriptome analysis, which we think should be the future of precision oncology. The next steps in our research is to provide a nice base around multigene panels in terms of multigene versus single-gene testing, whether that be colorectal cancer, lung cancer, melanoma, etc., and to map out the entire system implications of implementing next-generation sequencing panels. And then we want to answer the questions around, “Well, what if we do exomes for all patients? What if we do whole genomes and transcriptomes for all patients? What are the comparative outcomes for a true tumor-agnostic precision oncology approach, accounting for, as you say, things like return of results with respect to hereditary cancers?” I think the challenge that's going to be encountered is really around the persistent high costs of something like a whole-genome and transcriptome sequencing approach. Although we do see the technology prices going down—the "$1,000 genome" or “$6,000 genome" on whatever Illumina machine you might have—that bioinformatics is continuing to be expensive. And so, there are pipelines that are automated, of course, and you can create a targeted gene report really rapidly within a reasonable turnaround time. But of course, for secondary or what I call level two analysis, that bioinformatics is going to continue to be expensive. And so, we're just continually asking that question is: In our healthcare system and in other healthcare systems, if you want to take a precision oncology approach, how do you create the pipelines? And what types of technologies really lend themselves to benefits over and above next-generation sequencing or multigene panels, allowing for access to off-label therapies? What does that look like? Does that actually improve patients? I think some of the challenges, of course, is because of heterogeneity, small benefiting populations, finding a signal if a signal is indeed there is really challenging. And so, what we are thinking through is, with respect to real-world evidence methods and emulating randomized controlled trials, what types of evidence methods actually allow us to find those signals if indeed those signals are there in the context of small benefiting populations? Dr. Rafeh Naqash:Thank you so much, Dean. Sounds like a very exciting field, especially in the current day and age where cost-effectiveness, financial toxicity is an important aspect of how we improve upon what is existing in oncology. And then lots more to be explored, as you mentioned. The last minute and a half I want to ask about you as an individual, as a researcher. There's very few people who have expertise in oncology, biomarkers, and health economics. So could you tell us for the sake of our trainees and early career physicians who might be listening, what was your trajectory briefly? How did you end up doing what you're doing? And maybe some advice for people who are interested in the cost of care, the cost of oncology drugs - what would your advice be for them very briefly? Dr. Dean Regier:Sure. So I'm an economist by training, and indeed I knew very little about the healthcare system and how it works. But I was recruited at one point to BC Cancer, to British Columbia, to really try to understand some of those questions around costs, and then I learned also around cost-effectiveness. And so, I did training in Scotland to understand patient preferences and patient values around quality of care, not just quantity of life, but also their quality of life and how that care was provided to them. And then after that, I was at Oxford University at the Nuffield Department of Population Health to understand how that can be incorporated into randomized control trials in children. And so, I did a little bit of learning about RCTs. Of course, during the way I picked up some epidemiology with deep understanding of what I call econometrics, what others might call biostatistics or just statistics. And from there, it was about working with clinicians, working with epidemiologists, working with clinical trialists, working with economists to understand the different approaches or ways of thinking of how to estimate efficacy, effectiveness, safety, and cost-effectiveness. I think this is really important to think through is that we have clinical trialists, we have people with deep understanding of biostatistics, we have genome scientists, we have clinicians, and then you add economists into the mix. What I've really benefited from is that interdisciplinary experience, meaning that when I talk to some of the world's leading genome scientists, I understand where they're coming from, what their hope and vision is. And they start to understand where I'm coming from and some of the tools that I use to understand comparative effectiveness and cost-effectiveness. And then we work together to actually change our methods in order to answer those questions that we're passionate about and curious about better for the benefit of patients. So, the short answer is it's been actually quite a trajectory between Canada, the UK. I spent some time at the University of Washington looking at the Fred Hutch Cancer Research Center, looking at precision oncology. And along the way, it's been an experience about interdisciplinary research approaches to evaluating comparative outcomes. And also really thinking through not just at one point in time on-off decisions—is this effective? Is it safe? Is it cost-effective?—not those on-off decisions, but those decisions across the lifecycle of a health product. What do those look like at each point in time? Because we gain new evidence, new information at each point in time as patients have more and more experience around it. And so what really is kind of driving our research is really thinking about interdisciplinary approaches to lifecycle evaluation of promising new drugs with the goal of having these promising technologies to patients sooner in a way that is sustainable for the healthcare system. Dr. Rafeh Naqash:Awesome. Thank you so much for those insights and also giving us a sneak peek of your very successful career. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Trying to manage content for multiple brands without losing your mind? In this episode, I'm sharing how I'm using ChatGPT and Trello to run three brands with more ease and less chaos. From my content framework to behind-the-scenes systems, this is your peek into what's working, what's not, and how I'm staying (mostly) sane through it all. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here BUSINESS NUGGET: Starts at 15:50 EPISODES YOU MIGHT ALSO ENJOY... EPISODE 517 – BOOKS, BOUNDARIES & BROKEN TRUST: A BUSINESS OWNER'S WEEK IN REVIEW  EPISODE 508 – HOW CHATGPT BLEW MY MIND EPISODE 468 – DEFINING YOUR NICHE EPISODE 418 – MUST HAVE MONEY HABITS EPISODE 368 – EXCLUSIVE SNEAK – THE FIRST CHAPTER OF MY BOOK EPISODE 318 – WHY WORKFLOWS IN BUSINESS ARE IMPORTANT EPISODE 268 – THERE'S ALWAYS AN OPTION B EPISODE 218 – THE IMPORTANCE OF FAILURE EPISODE 168 – GOING AFTER YOUR DREAMS EPISODE 118 – HOW TO MAKE MONEY AS A BLOGGER FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

In this episode of "Past Deadline," Podcast Editor, Christian Valk, sit down with graduating News Editor, Courtney Boyd, and incoming News Editor, Blace Carpenter to tackle the often-sensitive topic of salary.

In this episode of "Past Deadline" for the may print edition Podcast Editor, Christian Valk, sits down with Sports Editor, Sydney Neal and Beat Reporter, Noah Henson, to talk about the athletics budget and their discoveries.

Hey friend! In today's episode, we're going all-in: book recs, blooming sunflowers, growing pains in business, and a tough decision I had to make as a boss. I'm sharing real talk about letting someone go, content growth updates, and where I'm at with the 5-day email challenge that's gonna help you build your own freebie funnel. Let's unpack all the layers together. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here BUSINESS NUGGET: Starts at 14:10 EPISODES YOU MIGHT ALSO ENJOY... EPISODE 516 – THE AI ASSISTANT THAT UNDERSTOOD MY BRAND BETTER THAN I COULD EPISODE 507 – HOW TO USE INSTAGRAM TRIAL REELS & MORE EPISODE 467 – CONTENT CREATION HACK EPISODE 417 – HOW TO STEP INTO YOUR OWN POWER EPISODE 367 – HOW TO MAXIMIZE YOUR TIME DURING A SLOW SEASON EPISODE 317 – WHAT I WOULD DO DIFFERENT IN BIZ IF STARTING NOW EPISODE 267 – YOU ARE NOT STARTING OVER EPISODE 217 – STOP TRYING TO DO ALL THE THINGS EPISODE 167 – HOLIDAY MARKETING STRATEGIES USING PINTEREST EPISODE 117 – NITTY GRITTY SERIES WITH CAMILLE WHITING FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative  

Send us a textIn this episode, Anika Zubair discusses the vital collaboration between customer success and marketing with guest Ashna Patel. They explore how aligning these two functions can drive growth, retention, and upsells. Ashna shares her journey from customer success to marketing, emphasizing the importance of messaging and cross-functional teamwork in enhancing the customer experience. The conversation highlights the need for customer success professionals to leverage marketing resources and insights to better serve their customers and achieve organizational goals. In this conversation, the speakers discuss the critical alignment between marketing and customer success teams, emphasizing the importance of collaboration to enhance customer retention and product adoption. They explore how effective messaging and nurturing relationships can drive growth, and the role of AI in shaping the future of customer success. The discussion highlights practical strategies for cross-functional collaboration and the need for open communication to ensure that both teams work towards common goals.Signup to the VIP Waitlist for RevUP Academy: https://thecustomersuccesspro.com/revupTimestamps:00:00 Introduction 02:52 Ashna Patel's Transition from Customer Success to Marketing06:06 Understanding the Bow Tie Model in Customer Journey09:10 The Role of Marketing in Customer Success11:53 The Importance of Messaging in Customer Engagement15:02 Aligning Marketing and Customer Success Teams17:54 Leveraging Marketing for Customer Retention and Growth20:54 Building Cross-Functional Relationships for Success32:39 Team Alignment for Customer Success35:05 Marketing's Role in Customer Retention39:55 Nurturing Customer Relationships42:04 Effective Messaging Strategies48:15 Cross-Functional Collaboration for Success55:30 Conclusion and Key TakeawaysConnect with Anika:LinkedInYouTubeTikTokInstagramWebsite: thecustomersuccesspro.comCoaching with Anika: CSM RevUP AcademyConnect with Ashna Patel:https://www.linkedin.com/in/ashnapatel92/Ashna Patel is a former award-winning Customer Success leader turned Marketer, bringing over a decade of experience in customer engagement, retention, and growth. After years of driving customer success strategies, she transitioned into marketing to bridge the gap between pre- and post-sales, leveraging her deep understanding of customer needs to fuel demand generation and customer marketing. Apart from this, Ashna is also passionate about helping professionals build personalized systems to prevent burnout, enhance productivity, and achieve sustainable success (personally and professionally).  Podcast Editor: https://podcastmagician.com/

This week, I'm taking you behind the scenes of a brand breakthrough — thanks to ChatGPT. From refining my niche to mapping out content pillars and uncovering my ideal audience, this is the real talk on how AI helped me get clear (and why it might help you, too). Oh, and there's a tech rant or two. Let's dive in. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here EPISODES YOU MIGHT ALSO ENJOY... EPISODE 515 – YOUR NICHE ISN'T THE PROBLEM EPISODE 506 – I WENT VIRAL OVER A LIGHT BULB…  EPISODE 466 – SIMILAR STRATEGIES BETWEEN EMAIL & IG STORIES EPISODE 416 – HOW TO GET OUT OF YOUR OWN WAY EPISODE 366 – HOW TO PERFORM A MID-YEAR REVIEW EPISODE 316 – PREPARING FOR THE 2ND HALF OF THE YEAR EPISODE 266 – THE POWER OF YOUR ATTITUDE EPISODE 216 – STARTING SMALL & FINDING SUCCESS EPISODE 166 – CREATING A PLAN FOR Q3 & Q4 EPISODE 116 – KEEPING YOURSELF SANE FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

Struggling to stand out online? It's not your niche—it's your clarity. In this episode, I'm sharing real talk on what it actually takes to find your place online, why niching down doesn't mean boxing yourself in, and how to show up in a way that feels true to you. Plus, updates from the garden, the barndo build, and what I've been reading lately. Let's dig into the good stuff.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Polygenic Risk Scores in Myocardial Injury After Noncardiac Surgery: A VISION Substudy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Aerobic Exercise Training, Biological Age, and Mortality in Chronic Heart Failure With Reduced Ejection Fraction.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Chronic Inflammatory-Related Disease and Cardiovascular Disease in MESA.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Achieved Diastolic Blood Pressure and Cardiovascular Outcomes in Elderly Patients With Hypertension.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Increased Endothelin-1 Is Associated With Morbidity in Single Ventricle Heart Disease in Children Undergoing Fontan Palliation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Characteristics and Survival Outcomes of Hepatocellular Carcinoma After the Fontan Operation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Third-Trimester NT-proBNP for Pre-eclampsia Risk Prediction: A Comparison With sFlt-1/PlGF in a Population-Based Cohort.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Gestational Blood Pressure Trajectories and 5-Year Postpartum Hypertension Risk in the MADRES Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Cardiac Tamponade Complicating Type A Acute Aortic Dissection: Insights From 25 Years of Registry Research.

Hosts Jon Negroni and Travis Hymas reunite (finally!) to talk through the chaos, carnage, and character drama in One Piece Chapters 1145 “Wildfire in Forest Sector 2, Branch Route 8” and 1146 “Motion in Stillness.” After a month-long break, the duo break down Gunko’s shocking fight with the Straw Hats, Loki’s past encounter with Rocks D. Xebec, and why Elbaf may be headed toward all-out war. Also on deck: is Dr. Hiriluk secretly Xebec?? Jon pitches the reddit theory. Travis pretends to like it. Topics this week include: Usopp and Nami step up against a full-on god (and pay the price). Gunko’s creepy regeneration powers...do the Holy Knights have Gorosei buffs? Loki’s backstory reveals…Rocks D. Xebec?? Jimbei being the MVP firefighter. Brook possibly knowing more than he lets on about Holy Knights. King Harald’s deal with the Celestials and the mystery of Elbaf’s true allegiance. Why Robin and Chopper are in stealth mode. Plus: Fan comments, wild theories, and the pressing question: are the Straw Hats about to get wrecked again? Catch up before Chapter 1147 drops, and don’t forget to join our spoiler-filled One Piecechannel in the InBetweenDrafts Discord linked right here! You can also email your questions, corrections, and theories via email: rookiepirateradio@gmail.com. We’ll be back to discuss the next chapter after it comes out, but in the meantime, be sure to subscribe to Rookie Pirate Radio on your favorite podcast app, so you can stay up to date on all our releases. Extra Credits: Our intro music is a remix version of “Overtaken” from the One Piece anime, cut together by Jon Negroni. Our podcast artwork is by Jon Negroni. Travis Hymas is the Anime & Manga editor of InBetweenDrafts, and Jon Negroni is the Podcast Editor of InBetweenDrafts. Our recap of One Piece 1145-1146 is based on the English translation of the manga, courtesy of Viz. In case you didn’t know already, Eiichiro Oda is the creator of One Piece. Plus, we’re not just a One Piece podcast by the way! If you have a manga or anime you’d like us to cover or mention on the show, definitely reach out.See omnystudio.com/listener for privacy information.

You're not annoying — you're remindable. In this episode, I break down why sharing your offers often isn't spam, it's strategy. Inspired by a viral reel (and 4 emails from Old Navy), I'm giving you a pep talk on showing up, being seen, and marketing like a pro — even to friends and family. Don't fail because you're afraid to share. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here RESOURCE: Convert visitors into subscribers with OPTINMONSTER EPISODES YOU MIGHT ALSO ENJOY... EPISODE 513 – WHY INSTAGRAM ALONE ISN'T ENOUGH EPISODE 504 – MAKING TIME FOR YOURSELF & MORE EPISODE 464 – TRUTH IN ADVERTISING ONLINE EPISODE 414 – THE DARK SIDE OF ENTREPRENEURSHIP & BALANCE EPISODE 364 – PINTEREST TIPS EPISODE 314 – BENEFITS OF CO-WORKING SESSIONS EPISODE 264 – BUSINESS WISDOM THROUGH 5 YEARS OF PODCASTING EPISODE 214 – WHY IT'S TIME FOR YOU TO HIRE A BIZ COACH EPISODE 164 – ARE ALL YOUR EGGS IN ONE BASKET? EPISODE 114 – DECIDING TO REBRAND FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

This week, I'm getting real about Instagram's latest changes, what it means for creators + small business owners, and why betting everything on one platform is just plain risky. I'm sharing what changed on Instagram and how it's impacting creators; why building across multiple platforms is non-negotiable; how I'm compounding my content for more reach with less burnout and a peek into my updated bio, brand focus, and weekly content goals. Whether you're a flower farmer, content creator, or small biz owner, there's a nugget in here for you. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here RESOURCE: Convert visitors into subscribers with OPTINMONSTER EPISODES YOU MIGHT ALSO ENJOY... EPISODE 512 – MAKING SPACE FOR YOURSELF EPISODE 503 – COMPOUNDING INTEREST…BUT WITH SOCIAL MEDIA EPISODE 463 – CREATING BINGEABLE CONTENT EPISODE 413 – THE DARK SIDE OF ENTREPRENEURSHIP & RELATIONSHIPS EPISODE 363 – A PROCESS FOR SETTING UP A FUNNEL EPISODE 313 – TIPS FOR BUILDING YOUR TEAM AS A CREATIVE EPISODE 263 – STAYING PREPARED IN BUSINESS EPISODE 213 – DEFINING YOUR NICHE EPISODE 163 – WHY NETWORKING MATTERS EPISODE 113 – THE NITTY GRITTY WITH VILMA GONZALEZ FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

I traveled by myself and I survived. I just returned from my Spring Round Top buying trip and it was the first time to do it solo in close to 10 years. I've done day trips by myself when I first started going, but I've never traveled by myself for a week. And I learned some things about myself. Tune in. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here RESOURCE: Convert visitors into subscribers with OPTINMONSTER EPISODES YOU MIGHT ALSO ENJOY... EPISODE 511 – FEARLESS VISIBILITY IN YOUR BUSINESS EPISODE 502 – SHORT FORM CONTENT TIPS EPISODE 462 – JUST START EPISODE 412 – THE HOW OF MY BUSINESS JOURNEY EPISODE 362 – WHY CONTENT STRATEGY MATTERS EPISODE 312 – 9 THINGS I LEARNED FROM THE BIGGEST EVENT OF MY CAREER EPISODE 262 – UNCONVENTIONAL BUSINESS UNICORNS EPISODE 212 – THE 4 P'S YOU NEED IN BIZ EPISODE 162 – FUNDAMENTALS OF BLOGGING EPISODE 112 – ESSENTIAL BLOG MAINTENANCE TASKS FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative

I was chatting with a friend the other day and mentioned a few not-so-nice comments I got recently on TikTok and YouTube. She kind of shrugged and said, “Well, you do live your life online,” and that really stuck with me. Running a business online is already hard — the pressure, the visibility, the vulnerability. Add unkind or straight-up mean comments on top of that, and no wonder so many of us hesitate to show up fully as ourselves. But here's the thing: choosing to share online doesn't mean we're inviting people to attack or tear us down. In this episode, I'm talking about what it really looks like to overcome the fear of being seen in your business — and how to keep showing up, even when it feels hard. RESOURCES MENTIONED NOTE: Some links below contain affiliate/referral links. It is a way for this site to earn advertising fees by advertising or linking to certain products and/or services. DISCOUNT: Code for 30+ free days of Podcast Audio Hosting through Libsyn: bossgirl RESOURCE: Need a Podcast Editor? Hire mine & tell him I referred you…The Podcast Man HIRE ME: Back Pocket VIP Coaching YOUTUBE CHANNEL: Subscribe >> The House of Sugar Creek MY BOOK: Snag a copy! Pillars & Purpose: How to Build a Business That Works for You RESOURCE: Contract Templates for your Business YOUTUBE CHANNEL: Subscribe to the BGC YouTube Channel and listen to my episodes via YouTube! MY 90-DAY UNDATED PLANNER: Buy it here! RESOURCE: Receive 20% off your first month or your first year with Dubsado RESOURCE: Freebie: How to Price for Profit Worksheet RESOURCE: Freebie: Create a years worth of Content in Minutes LEAVE A MESSAGE: Click Here RESOURCE: Convert visitors into subscribers with OPTINMONSTER EPISODES YOU MIGHT ALSO ENJOY... EPISODE 510 – BUSINESS STRATEGIES FOR GROWTH EPISODE 501 – HOW TO ROMANTICIZE YOUR LIFE EPISODE 461 – EVERYTHING TO KNOW ABOUT AFFILIATE MARKETING EPISODE 411 – THE DARK SIDE OF ENTREPRENEURSHIP & PRODUCTIVITY EPISODE 361 – EMAIL MARKETING NURTURE SEQUENCE EXPLAINED EPISODE 311 – STOP BEING A CARBON COPY EPISODE 261 – ATTRACTING DREAM CLIENTS EPISODE 211 – THE POWER OF AUTHENTICITY EPISODE 161 – PIVOT MOMENTS EPISODE 111 – THE NITTY GRITTY SERIES WITH LAUREN MCBRIDE FIND TAYLOR ONLINE... Blog – The House of Sugar Creek Instagram – @taylorlbradford Facebook – bossgirlcreative Pinterest – thehouseofsugarcreek TikTok – @taylorlbradford YouTube – The House of Sugar Creek YouTube – Boss Girl Creative